Secukinumab-associated localized granuloma annulare (SAGA): a case report and review of the literature

Review of secukinumab‐induced adverse events of special interest and its potential pathogenesis

“…The onset time of those AESI ranged from 3 days 52 to 96 weeks 60 . A total of 24 AESI was identified (Table 1), including adiposity, 14 alopecia areata, 15 acute autoimmune hemolytic anemia, 16 bullous eruption, 17,18,32 crystalline corneal deposition, 19 drug‐associated vasculitis (including leucocytoclastic vasculitis, IgA vasculitis [henoch‐schönlein purpura], and Behcet's disease), 5,20–24,61 eczematous drug eruption, 11,25–31,62 erectile dysfunction, 35 granuloma annulare, 36–38 hidradenitis suppurativa, 39,40 hypertrichosis, 41 IBD (including Crohn disease [CD], ulcerative colitis [UC], and IBD undefined [IBDU]), 9,12,13 interstitial pneumonia, 42,43 drug‐induced lupus erythematosus, 6,45–47 multiple lentigines, 48 perianal dermatophytosis, 51 pompholyx (dyshidrotic eczema), 33,34 pseudolymphoma, 52 pyoderma gangrenosum, 53,54 raynaud's phenomenon, 55 scleroderma, 57 stomatitis (such as lichenoid mucositis, oral lichen planus, and angular cheilitis), 44,49,50,56 uveitis, 58 and vitiligo 59,60 …”

“…The searches generated 1426 potentially articles that matched our predefined search strategy, of which 55 were included in this review (Figure 1): 2 clinical studies, 11,12 2 review, 9,13 50 case reports 5,6,14–61 and 1 case series, 62 published between 2016 and 2021. More than 1077 patients (aged 18–74 years) experienced AESI after secukinumab treatment for Ps, PsA, AS, spondyloarthritis (SpA), and/or palmoplantar psoriasis (PPP).…”

Secukinumab‐induced scar sarcoidosis in a patient with plaque psoriasis

“…1 Still, newer IL-17 inhibitors have also been found to paradoxically trigger inflammatory diseases, mostly psoriasiform and eczematous reactions, and rarely granulomatous reactions. [1][2][3][4][5][6] To date, there are few reports of sarcoidosis observed with IL-17 inhibitors, four of them occurring with secukinumab. [1][2][3][4][5] Time to onset varied from 3.25 to 19.6 months.…”

“…1 There have also been reports of granuloma annulare associated with IL-17 inhibitors. 1,6 Several cases of other granulomatous conditions induced by IL-17 inhibition have also been described, 1,6,7 namely the development and exacerbation of inflammatory bowel disease further emphasising the role of IL-17 inhibition in the development of granulomatous reactions. 7 Our patient developed sarcoidosis after 20 months of treatment with secukinumab.…”

Recalcitrant granuloma annulare induced by two different biologic agents resolved after Janus kinase inhibitor treatment

“…1 There are more cases of GA caused by biologic treatment reported (Table 1). [2][3][4][5][6] Based on the literature, paradoxically induced GA appears to be most common in patients undergoing biologic treatment of rheumatoid arthritis. 3 We present a case of a 57-year-old woman in whom both of two different biologic agents caused paradoxical formation of GA lesions.…”